9,15 Evidence suggests that the pathologic molecular pathways associated with the Chr1 and Chr10 loci are distinct and that their respective contributions to clinical AMD manifestations, progression, and response to anti–vascular endothelial growth factor treatment differ markedly.16,17,18,19,20,21,22,23 It is essential to understand these differences more thoroughly to improve patient care and outcomes and to design more effective gene pathway-targeted therapeutics against AMD. The gene discussed is VEGFA; the disease is age-related macular degeneration.